A number of studies have shown that people infected with Mycobacterium tuberculosis (mTB) bacteria have a lower incidence of asthma and allergy.  In order to survive within the human body mTB  has evolved to switch off immuno-inflammatory processes by reducing the body’s natural immune responses of inflammation and hypersensitivity, without detrimental effects on the human host. Peptinnovate’s patented technology utilises that in-built efficacy and safety profile.